HSBC Downgrades Lilly as Obesity Market Faces Pricing Pressures
TL;DR
HSBC analyst Rajesh Kumar downgraded Eli Lilly (LLY) from Hold to Sell, arguing that pricing dynamics and a downsized total addressable market, intensified competition from Novo Nordisk, and potential headwinds for Lilly’s oral obesity drug orforglipron could limit upside; he cut the price target from $1,070 to $850 as TAM is viewed at about $80–120B versus consensus around $150B+, while the broader market remains bullish with a Strong Buy consensus and ~36% upside over the next year.
- ‘Run for the Hills,’ Says Analyst About Eli Lilly Stock (LLY) TipRanks
- Eli Lilly Stock Gets Downgraded. It Faces Stiff Headwinds After Strong Run-Up. Barron's
- With downgrade, HSBC casts doubt about Lilly's 'stairway to heaven' trajectory Fierce Pharma
- Eli Lilly (LLY) Stock Declines While Market Improves: Some Information for Investors Yahoo Finance
- Eli Lilly catches a downgrade as HSBC warns of an overhyped obesity drug market CNBC
Want the full story? Read the original reporting
Read on TipRanks